Results 201 to 210 of about 1,348 (287)

Surgical Procedures and Medical Treatments Among Patients With Hidradenitis Suppurativa Before and After Referral to Specialised Dermatological Hospital Care: A Nationwide Registry Study

open access: yesJEADV Clinical Practice, EarlyView.
Hidradenitis suppurativa (HS) is often diagnosed late, complicating management. In this nationwide Danish study including 10,196 patients with dermatologist‐verified HS, we examined treatment patterns before and after referral to specialised hospital care.
Nana A. L. Rosenø   +8 more
wiley   +1 more source

Concurrent Psoriasis and Dermatomyositis: Retrospective Analysis and Literature Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis (PsO) and dermatomyositis (DM) are both autoimmune‐mediated, inflammatory conditions. The concurrence of PsO and DM is rare, and literature on their relationship remains limited. Additionally, cutaneous DM can be challenging to clinically diagnosis, often presenting with psoriasiform clinical features.
Emily R. Gordon   +5 more
wiley   +1 more source

Stellar Flares, Superflares and Coronal Mass Ejections – Entering the Big Data Era

open access: green
K. Vida   +8 more
openalex   +2 more sources

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin   +4 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender   +2 more
wiley   +1 more source

Exploring the sub-Neptune frontier with JWST. [PDF]

open access: yesProc Natl Acad Sci U S A
Madhusudhan N   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy